POLD1 and colorectal cancer: For instance, in colorectal cancer, POLD1 exonuclease domain mutations (e.g., p.S478N, p.L474P) correlate with elevated TMB and robust CD8+ T-cell infiltration, driving durable responses to anti-PD-1 therapy despite MSS status (64).